 pharmacolog intraven oral etoposid epipodophyllotoxin deriv etoposid widespread use combin chemotherapi past decad phase-specif cytotox last phase cell cycl mode action certain break dna interact dna-topoisomeras II format free radic studi biexponenti decay intraven IV administr etoposid administ etoposid present urin etoposid avail oral IV prepar schedule-depend once-daili dose day day result superior intermitt administr bioavail oral etoposid absorpt linear dose mg/d bioavail decreas factor bioavail oral etoposid patient statu concurr medic hepat renal function nausea vomit numer clinic trial etoposid excel activ rang tumor small cell lung cancer sclc malign lymphoma gestat trophoblast tumor ewe soft tissu sarcoma germ cell tumor modest activ tumor non-sclc compar studi avail data oral daili day similar IV prepar rang activ studi elderli patient sclc etoposid mg/d time respons rate median surviv month result similar intens IV regimen sever studi chronic oral etoposid time respons sclc germ cell tumor patient standard etoposide-contain regimen data etoposid new drug schedul high respons rate oral etoposid oral administr IV administr substitut flexibl chemotherapeut administr hospit accept toxic